



# STATE OF TENNESSEE

2022 Episodes of Care Results

# Results of Episodes of Care Program

<h2>CY 2015</h2>	<h2>CY 2016</h2>	<h2>CY 2017</h2>	<h2>CY 2018</h2>
<p><i>Estimated Savings*:</i>  <b>\$10.8 million</b></p> <ul style="list-style-type: none"> <li>Providers and hospitals reduced costs while maintaining quality of care.</li> <li>Gain-sharing payments to providers exceeded risk-sharing payments by <b>\$280,000.</b></li> </ul> <p>Includes the 3 episodes in performance in CY 2015</p>	<p><i>Estimated Savings*:</i>  <b>\$14.5 million</b></p> <ul style="list-style-type: none"> <li>Quality metrics <b>improved</b> for perinatal, total joint replacement, and COPD, and were mostly maintained for the remaining episodes.</li> <li>Gain-sharing payments to providers exceeded risk-sharing payments by <b>\$395,000.</b></li> </ul> <p>Includes the 8 episodes in performance in CY 2016</p>	<p><i>Estimated Savings*:</i>  <b>\$28.6 million</b></p> <ul style="list-style-type: none"> <li>Quality metrics <b>improved</b> or maintained for most episodes.</li> <li>Gain-sharing payments to providers exceeded risk-sharing payments by <b>\$206,900.</b></li> </ul> <p>Includes the 19 episodes in performance in CY 2017</p>	<p><i>Estimated Savings*:</i>  <b>\$38.3 million</b></p> <ul style="list-style-type: none"> <li>Quality metrics <b>improved</b> or maintained for most episodes.</li> <li>Gain-sharing payments to providers exceeded risk-sharing payments by <b>\$686,000.</b></li> </ul> <p>Includes the 27 episodes in performance in CY 2018</p>



\*Compared to 3% projected medical cost trend

# Results of Episodes of Care Program

<p align="center"><b>CY 2019</b></p> <p><i>Estimated Savings*:</i> <b>\$45.2 million</b></p>	<p align="center"><b>CY 2020</b></p>	<p align="center"><b>CY 2021</b></p>	<p align="center"><b>CY 2022</b></p> <p><i>Estimated Savings**:</i> <b>\$52.9 million</b></p>
<ul style="list-style-type: none"> <li>Quality metrics <b>improved</b> or maintained for most episodes.</li> <li>Gain-sharing payments totaled <b>\$1.9 million</b>.</li> <li>Due to COVID-19, all risk-sharing payments were waived.</li> </ul>	<p align="center">Due to the COVID-19 pandemic, estimated savings were not calculated for the 2020 and 2021 performance periods.</p> <ul style="list-style-type: none"> <li>In order to continue to support providers during the unprecedented health and economic crisis, the three TennCare Managed Care Organizations (MCOs) waived all risk-sharing payments for the 2019, 2020 and 2021 performance years. All gain-sharing payments were made as earned. Estimated savings were not calculated.</li> </ul>		<ul style="list-style-type: none"> <li>Quality metrics <b>improved</b> or maintained for most episodes.</li> <li>Gain-sharing payments totaled <b>\$1.9 million</b>. Risk-sharing payments totaled <b>\$2.5 million</b>.</li> </ul>
<p>Includes the 45 episodes in performance in CY 2019</p>	<ul style="list-style-type: none"> <li>Gain sharing payments totaled <b>\$1.1 million</b>.</li> <li>Due to COVID-19, all risk-sharing payments were waived.</li> </ul>	<ul style="list-style-type: none"> <li>Gain sharing payments totaled <b>\$1.4 million</b>.</li> <li>Due to COVID-19, all risk-sharing payments were waived.</li> </ul>	<p>Includes the 43 episodes in performance in CY 2022</p>

Since the beginning of the Episodes of Care program, total gain-sharing payments to providers have exceeded total risk-sharing payments by **\$5.4 million**.



\*Compared to 3% projected medical cost trend

\*\*Compared to 3% projected medical cost trend, with 1.5% projected medical cost trend for CY2020 and CY2021 due to COVID-19 pandemic



# SAVINGS RESULTS

# 2022 Episodes Savings

Estimated savings for 2022 is approximately **\$52.9 million** due to Episodes' risk-adjusted cost being less than projected medical trend of a 3% annual increase

Episode Type	Projected	Actual	Estimated Savings per Episode	Percent Savings per Episode	Number of Valid Episodes	Total Estimated Savings
<b>Total</b>	-	-	-	-	<b>669,933</b>	<b>\$52,900,079</b>
Asthma Acute Exacerbation	\$1,448	\$928	\$521	36.0%	8,892	\$4,630,665
Perinatal	\$8,233	\$7,120	\$1,113	13.5%	15,216	\$16,940,374
Total Joint Replacement	\$14,906	\$10,698	\$4,208	28.2%	221	\$929,884
Cholecystectomy	\$5,395	\$4,868	\$527	9.8%	1,701	\$896,759
Colonoscopy	\$1,289	\$1,020	\$269	20.9%	2,495	\$671,337
COPD	\$2,771	\$2,232	\$539	19.4%	1,838	\$989,768
Acute PCI	\$10,871	\$12,638	-\$1,767	-16.3%	218	-\$385,220
Gastrointestinal Hemorrhage	\$4,132	\$2,771	\$1,361	32.9%	1,038	\$1,413,053
Pneumonia	\$1,419	\$1,747	-\$328	-23.1%	1,813	-\$594,367
Respiratory Infection	\$140	\$133	\$7	4.7%	288,937	\$1,906,295
EGD	\$1,404	\$1,165	\$239	17.0%	6,406	\$1,532,177
UTI - Inpatient	\$4,732	\$6,292	-\$1,560	-33.0%	1,545	-\$2,410,071
UTI - Outpatient	\$175	\$134	\$41	23.2%	31,242	\$1,268,942
Bariatric Surgery	\$9,082	\$6,691	\$2,391	26.3%	594	\$1,420,533
ADHD	\$1,450	\$1,115	\$335	23.1%	21,013	\$7,038,411
CHF Acute Exacerbation	\$6,661	\$6,948	-\$287	-4.3%	1,780	-\$511,271
ODD	\$1,535	\$901	\$634	41.3%	1,360	\$862,425
Breast Biopsy	\$1,948	\$1,625	\$323	16.6%	901	\$291,382
Otitis Media	\$177	\$148	\$29	16.4%	117,899	\$3,424,028
Tonsillectomy	\$2,973	\$2,580	\$393	13.2%	5,523	\$2,172,774
Diabetes Acute Exacerbation	\$6,146	\$5,843	\$303	4.9%	1,144	\$346,966
Pancreatitis	\$6,784	\$6,475	\$308	4.5%	839	\$258,693
Skin and Soft Tissue Infection	\$246	\$222	\$24	9.9%	37,775	\$920,950

# 2022 Episodes Savings

Estimated savings for 2022 is approximately **\$52.9 million** due to Episodes' risk-adjusted cost being less than projected medical trend of a 3% annual increase

Episode Type	Projected	Actual	Estimated Savings per Episode	Percent Saving per Episode	Number of Valid Episodes	Total Estimated Savings
<b>Total</b>	-	-	-	-	<b>669,933</b>	<b>\$52,900,079</b>
Knee Arthroscopy	\$3,464	\$3,725	-\$262	-7.6%	996	-\$260,796
Non-Operative Ankle Injury	\$347	\$321	\$26	7.4%	15,551	\$399,776
Non-Operative Knee Injury	\$434	\$399	\$35	8.1%	7,963	\$281,105
Non-Operative Shoulder Injury	\$370	\$335	\$36	9.6%	6,836	\$242,982
Non-Operative Wrist Injury	\$395	\$339	\$56	14.1%	8,587	\$477,805
Spinal Fusion	\$23,126	\$17,420	\$5,706	24.7%	360	\$2,054,156
Spinal Decompression w/o Fusion	\$6,109	\$5,652	\$457	7.5%	200	\$91,371
Back/Neck Pain	\$427	\$406	\$20	4.7%	31,668	\$635,889
Acute Gastroenteritis	\$646	\$656	-\$9	-1.5%	18,759	-\$177,357
Acute Seizure	\$1,595	\$1,410	\$185	11.6%	4,924	\$911,555
Appendectomy	\$5,595	\$5,354	\$241	4.3%	1,127	\$272,131
Bronchiolitis	\$706	\$713	-\$7	-1.0%	4,174	-\$29,147
Colposcopy	\$405	\$444	-\$38	-9.5%	2,979	-\$114,534
GI Obstruction	\$9,702	\$6,238	\$3,464	35.7%	355	\$1,229,751
Hernia Repair	\$4,717	\$4,004	\$713	15.1%	1,432	\$1,020,965
Hysterectomy	\$5,567	\$5,619	-\$52	-0.9%	998	-\$52,243
Pediatric Pneumonia	\$987	\$985	\$2	0.2%	1,972	\$3,935
Syncope	\$723	\$501	\$221	30.6%	7,307	\$1,617,747
Acute Kidney & Ureter Stones	\$1,007	\$898	\$109	10.9%	1,951	\$213,220
Cystourethroscopy	\$954	\$906	\$48	5.0%	1,404	\$67,284



# QUALITY PERFORMANCE

# Episode gain-sharing Quality Metrics – Wave 1

Wave 1 Episodes*	CY 2014	CY 2015	CY 2016	CY 2017	CY 2018	CY 2019	CY 2020	CY 2021	CY 2022	Target Performance
<b>Perinatal (16,526 valid episodes)</b>										
1. HIV Screening (≥ 90%)	90.2%	88.3%	87.7%	89.1%	92.8%	94.6%	91.5%	87.2%	86.6%	<i>Higher is better</i>
2. Group B Streptococcus Screening (≥ 90%)	87.8%	85.9%	94.0%	95.5%	95.2%	96.7%	92.7%	92.1%	88.9%	<i>Higher is better</i>
3. C-Section Rate (≤ 38%)	30.5%	31.6%	30.6%	31.2%	30.8%	29.9%	29.6%	29.7%	29.8%	<i>Lower is better</i>
<b>Acute Asthma Exacerbation (8,917 valid episodes)</b>										
1. Follow-up Visit with Physician (≥ 30%)	N/A	N/A**	29.6%	30.3%	32.4%	30.8%	27.4%	30.6%	33.3%	<i>Higher is better</i>
2. Patient on Appropriate Medication (≥ 60%)	N/A	N/A**	60.3%	65.4%	69.5%	66.8%	62.8%	61.5%	66.8%	<i>Higher is better</i>
<b>Total Joint Replacement (256 valid episodes)</b>										
1. Admission Within the Post-Trigger Window 1 (≥ 10%)	N/A	N/A	N/A	N/A	N/A***	2.0%	3.1%	0.7%	0.8%	<i>Lower is better</i>

\*Valid episodes in 2022 performance period across all three MCOs.

\*\*There was a coding change to these quality metrics so there is no direct comparison to previous years.

\*\*\*There was not a quality metric tied to gain-sharing for this episode until the 2020 performance period.





# Episode gain-sharing Quality Metrics – Wave 2

Wave 2 Episodes*	CY 2015	CY 2016	CY 2017	CY 2018	CY 2019	CY 2020	CY 2021	CY 2022	Target Performance
<b>Cholecystectomy (1,728 valid episodes)</b>									
1. Hospitalization in Post-Trigger Window ( $\leq 10\%$ )	0.8%	1.0%	0.9%	0.3%	0.2%	0.3%	0.3%	0.1%	<i>Lower is better</i>
<b>COPD (1,862 valid episodes)</b>									
1. Follow-up Care Within Post-Trigger Window ( $\geq 45\%$ )	45.1%	46.7%	47.4%	46.7%	48.1%	44.6%	44.6%	46.1%	<i>Higher is better</i>
<b>Acute PCI (218 valid episodes)</b>									
1. Hospitalization in Post-Trigger Window ( $\leq 10\%$ )	1.0%	0.7%	0.7%	1.1%	0.9%	0.0%	0.7%	1.8%	<i>Lower is better</i>
<b>Non-acute PCI (54 valid episodes)</b>									
1. Hospitalization in Post-Trigger Window ( $\leq 10\%$ )	0.0%	1.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	<i>Lower is better</i>

**Note:** There are no quality metrics tied to gain-sharing for the colonoscopy episode.

\*Valid episodes in 2022 performance period across all three MCOs



# Episode gain-sharing Quality Metrics – Wave 3

Wave 3 Episodes*	CY 2016	CY 2017	CY 2018	CY 2019	CY 2020	CY 2021	CY 2022	Target Performance
<b>GI Hemorrhage (1,041 valid episodes)</b>								
1. Follow-up Care Within Post-Trigger Window (≥ 45%)	49.0%	51.9%	50.1%	50.0%	47.7%	47.6%	47.0%	Higher is better
<b>Pneumonia (1,824 valid episodes)</b>								
1. Follow-up Care Within Post-Trigger Window (≥ 30%)	N/A	N/A**	30.4%	30.4%	29.3%	27.9%	28.3%	Higher is better
<b>UTI-Inpatient (1,300 valid episodes)</b>								
1. Follow-up Care Within Post-Trigger Window (≥ 40%)	46.0%	43.5%	42.4%	41.1%	43.8%	41.5%	43.7%	Higher is better
<b>UTI-Outpatient (50,465 valid episodes)</b>								
1. Admission Within the Trigger Window for ED Triggered Episodes (≤ 5%)***	5.6%	6.1%	7.0%	6.3%	7.3%	6.7%	5.9%	Lower is better
2. Admission Within the Trigger Window for Non-ED Triggered Episodes (≤ 5%)***	0.8%	1.0%	1.0%	1.0%	0.9%	0.7%	0.6%	Lower is better
<b>Respiratory Infection (348,132 valid episodes)</b>								
1. ED Visit Within the Post-Trigger Window (≤ 10%)	N/A	N/A	N/A****	2.6%	2.2%	1.7%	1.9%	Lower is better
<b>EGD (6,460 valid episodes)</b>								
1. ED Visit Within the Post-Trigger Window (≤ 10%)	N/A	N/A	N/A****	4.0%	4.0%	3.4%	3.2%	Lower is better

\*Valid episodes in 2022 performance period across all three MCOs

\*\*There was a coding change to these quality metrics so there is no direct comparison to previous years.

\*\*\*This gain-sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.

\*\*\*\*There was not a quality metric tied to gain-sharing for this episode until the 2019 performance period.



# Episode gain-sharing Quality Metrics – Wave 4

Wave 4 Episodes*	CY 2016	CY 2017	CY 2018	CY 2019	CY 2020	CY 2021	CY 2022	Target Performance
<b>Bariatric Surgery (687 valid episodes)</b>								
1. Follow-up Care Within Post-Trigger Window (≥ 30%)	35.6%	37.4%	43.3%	43.0%	42.2%	45.0%	44.8%	Higher is better
<b>CHF Acute Exacerbation (1,793 valid episodes)</b>								
1. Follow-up Care Within Post-Trigger Window (≥ 60%)	56.2%	57.2%	57.0%	56.0%	54.6%	54.1%	54.8%	Higher is better
<b>ODD (1,519 valid episodes)</b>								
1. Minimum Care Requirement (≥ 30%)	26.7%	35.8%	31.9%	30.7%	34.4%	33.8%	30.6%	Higher is better
<b>CABG (81 valid episodes)</b>								
1. Follow-up Care Within Post-Trigger Window (≥ 90%)	71.4%	70.0%	78.5%	81.6%	88.3%	74.4%	70.4%	Higher is better
<b>Valve Repair and Replacement (31 valid episodes)</b>								
1. Follow-up Care Within Post-Trigger Window (≥ 90%)	78.5%	77.7%	76.7%	100.0%	63.6%	40.0%	71.0%	Higher is better
<b>ADHD (47,161 valid episodes)</b>								
1. Minimum Care Requirement (≥ 70%)	N/A**	78.5%	78.8%	77.6%	74.0%	76.2%	76.7%	Higher is better
2. Utilization of Therapy for Members Aged 4 and 5 Years (1 visit)***	N/A**	1.42	1.71	1.60	1.24	1.04	1.04	Higher is better
3. Long-acting Stimulants for Members Aged 6 to 11 Years (≥ 80%)***	N/A**	83.0%	83.1%	83.9%	82.7%	80.1%	86.4%	Higher is better
4. Long-acting Stimulants for Members Aged 12 to 20 Years (≥ 80%)***	N/A**	83.1%	82.9%	83.6%	80.7%	80.6%	84.4%	Higher is better

\*Valid episodes in 2022 performance period across all three MCOs

\*\*The preview period for the ADHD episode was 2017. The initial performance period for the ADHD episode was 2018.

\*\*\* This gain-sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.



# Episode gain-sharing Quality Metrics – Wave 5

Wave 5 Episodes*	CY 2017	CY 2018	CY 2019	CY 2020	CY 2021	CY 2022	Target Performance
<b>Breast Biopsy (905 valid episodes)</b>							
1. Appropriate Diagnostic Workup Rate (≥ 90%)	82.8%	80.8%	85.1%	83.5%	90.6%	92.4%	<i>Higher is better</i>
2. Core Needle Biopsy Rate (≥ 85%)**	77.5%	82.2%	92.0%	92.0%	91.3%	83.1%	<i>Higher is better</i>
<b>Tonsillectomy (5,523 valid episodes)</b>							
1. Bleeding Up to Two Days Following the Procedure (≤ 5%)	0.7%	0.5%	0.7%	0.7%	0.9%	0.02%	<i>Lower is better</i>
<b>Otitis Media (135,494 valid episodes)</b>							
1. Otitis Media with Effusion (OME) Episodes without Antibiotics Filled (≥ 25%)**	27.7%	26.2%	31.6%	35.2%	29.5%	27.1%	<i>Higher is better</i>
2. Non-OME Episodes with Amoxicillin (≥ 60%)**	64.3%	66.9%	65.1%	63.7%	66.0%	65.8%	<i>Higher is better</i>

\*Valid episodes in 2022 performance period across all three MCOs

\*\* This gain-sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.



# Episode gain-sharing Quality Metrics – Wave 6

Wave 6 Episodes*	CY 2017	CY 2018	CY 2019	CY 2020	CY 2021	CY 2022	Target Performance
<b>Skin and Soft Tissue Infection (42,764 valid episodes)</b>							
1. Bacterial Cultures when Incision and Drainage Performed (≥ 50%)**	42.4%	42.5%	40.7%	42.4%	43.3%	39.1%	Higher is better
2. SSTI Episodes with a First Line Antibiotic (≥ 85%)**	97.7%	97.8%	98.0%	97.6%	97.8%	97.6%	Higher is better
<b>HIV (1,122 valid episodes)</b>							
1. Periodic anti-retroviral therapy (ART) refill (≥ 85%)	71.6%	73.1%	73.8%	75.8%	69.8%	75.8%	Higher is better
<b>Diabetes Acute Exacerbation (1,150 valid episodes)</b>							
1. Follow-up care in the first 14 days of the post-trigger window (≥ 30%)	25.4%	30.6%	30.3%	27.9%	28.3%	46.0%	Higher is better
<b>Pancreatitis (842 valid episodes)</b>							
1. Follow-up care in the first 14 days of the post-trigger window (≥ 35%)	31.9%	35.8%	30.7%	32.9%	30.0%	47.4%	Higher is better

\*Valid episodes in 2022 performance period across all three MCOs

\*\* This gain-sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.



# Episode gain-sharing Quality Metrics – Wave 7

Wave 7 Episodes*	CY 2018	CY 2019	CY 2020	CY 2021	CY 2022	Target Performance
<b>Spinal Fusion (360 valid episodes)</b>						
1. Difference in Average MED/Day (≤ 8.0)	0.04	4.26	2.17	5.06**	0.81	Lower is better
<b>Spinal Decompression (200 valid episodes)</b>						
1. Difference in Average MED/Day (≤ 1.0)	1.38	5.71	1.40	-1.10	0.86	Lower is better
<b>Femur/Pelvic Fracture (147 valid episodes)</b>						
1. Related follow-up care (≥ 30%)	6.8%	9.6%	7.0%	5.1%	6.8%	Higher is better
2. Difference in Average MED/Day (≤ 8.0)	2.00	0.97	10.03	-7.44	0.89	Lower is better
<b>Knee Arthroscopy (996 valid episodes)</b>						
1. Difference in Average MED/Day (≤ 1.0)	-0.96	0.66	-0.47	0.30	0.92	Lower is better
<b>Non-operative Ankle Injury (15,969 valid episodes)</b>						
1. Difference in Average MED/Day (≤ 1.0)	0.02	0.38	0.87	0.09	0.94	Lower is better
<b>Non-operative Wrist Injury (8,767 valid episodes)</b>						
1. Difference in Average MED/Day (≤ 1.0)	0.11	0.47	0.19	0.96	0.92	Lower is better
<b>Non-operative Shoulder Injury (7,035 valid episodes)</b>						
1. Difference in Average MED/Day (≤ 1.0)	0.45	0.78	1.37	0.75	0.88	Lower is better
<b>Non-operative Knee Injury (8,124 valid episodes)</b>						
1. Difference in Average MED/Day (≤ 1.0)	0.73	0.05	1.01	0.76	0.92	Lower is better
<b>Back/Neck Pain (34,692 valid episodes)</b>						
1. Difference in Average MED/Day (≤ 1.0)	1.98	2.28	4.58	3.40	0.72	Lower is better

\*Valid episodes in 2022 performance period across all three MCOs

\*\*This quality metric is based on a formula related to opioid prescriptions. The increase for these metrics was driven by a few episode outliers that are being investigated and addressed by the Managed Care Organizations and aligned with TennCare’s overall opioid strategy. For more information on TennCare’s



Opioid Strategy, please visit the following website - <https://www.tn.gov/tenncare/tenncare-s-opioid-strategy.html>

# Episode gain-sharing Quality Metrics – Wave 8

Wave 8 Episodes*	CY 2018	CY 2019	CY 2020	CY 2021	CY 2022	Target Performance
<b>Acute Seizure (4,945 valid episodes)</b>						
1. Brain MRI Utilization in Focal Epilepsy ( $\geq 10\%$ )**	18.0%	18.7%	18.3%	16.1%	14.9%	Higher is better
2. Prolonged EEG Monitoring Utilization in Newly Diagnosed Seizure ( $\geq 10\%$ )**	7.4%	5.7%	2.8%	2.2%	3.7%	Higher is better
<b>Syncope (10,196 valid episodes)</b>						
1. Carotid Ultrasound Imaging in Adults ( $\leq 10\%$ )**	5.8%	4.0%	3.7%	3.4%	3.4%	Lower is better
<b>Bronchiolitis (4,179 valid episodes)</b>						
1. Related Admission during the Post-Trigger Window ( $\leq 10\%$ )	1.1%	1.1%	0.8%	0.7%	0.8%	Lower is better
2. Utilization of Bronchodilators ( $\leq 30\%$ )	14.4%	16.9%	13.0%	14.6%	17.9%	Lower is better
3. Utilization of Steroids ( $\leq 50\%$ )	22.0%	22.4%	20.4%	22.7%	27.5%	Lower is better
<b>Pediatric Pneumonia (1,983 valid episodes)</b>						
1. Related Admission during the Post-Trigger Window ( $\leq 10\%$ )	1.3%	1.2%	0.6%	0.9%	0.7%	Lower is better
2. Utilization of Macrolides in Patients Under 6 Years Old ( $\leq 30\%$ ) **	19.7%	20.7%	18.2%	17.0%	14.4%	Lower is better
3. Utilization of Narrow Spectrum Antibiotics ( $\geq 50\%$ )	52.0%	57.6%	56.7%	61.8%	65.0%	Higher is better

\*Valid episodes in 2022 performance period across all three MCOs

\*\* This gain-sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.



# Episode gain-sharing Quality Metrics – Wave 8

Wave 8 Episodes*	CY 2018	CY 2019	CY 2020	CY 2021	CY 2022	Target Performance
<b>Colposcopy (3,132 valid episodes)</b>						
1. LEEP Utilization Under 26 Years Old With No Evidence of High Grade Dysplasia ( $\leq 10\%$ )**	4.2%	4.2%	1.9%	1.6%	3.06%	Lower is better
2. LEEP Utilization with Low-grade Dysplasia ( $\leq 10\%$ )**	9.5%	7.0%	11.0%	13.2%	9.84%	Lower is better
<b>Hysterectomy (1,020 valid episodes)</b>						
1. Alternative Treatments ( $\geq 20\%$ )	31.0%	34.2%	43.7%	45.8%	65.32%	Higher is better
2. Related Follow-up Care ( $\geq 10\%$ )	19.2%	20.1%	22.2%	33.8%	34.41%	Higher is better
<b>GI Obstruction (355 valid episodes)</b>						
1. Related Follow-up Care ( $\geq 20\%$ )	33.0%	32.6%	35.6%	34.0%	36.34%	Higher is better
2. Difference in Average MED/Day ( $\leq 1.0$ )	4.13	3.31	3.53	4.08	0.89	Lower is better
<b>Appendectomy (1,128 valid episodes)</b>						
1. Abdominopelvic CT Scans in Children ( $\leq 50\%$ )**	42.4%	36.9%	39.2%	36.7%	43.07%	Lower is better
1. Difference in Average MED/Day ( $\leq 1.0$ )	-0.21	-0.09	1.55	-0.06	0.97	Lower is better
<b>Hernia Repair (1,433 valid episodes)</b>						
1. Difference in Average MED/Day ( $\leq 1.0$ )	0.12	0.63	1.39	-1.11	0.93	Lower is better
<b>Acute Gastroenteritis (18,911 valid episodes)</b>						
1. Abdominopelvic CT or MRI in Adults ( $\leq 40\%$ )**	N/A	41.1%	45.3%	47.5%	48.86%	Higher is better
2. Abdominopelvic CT or MRI in Children ( $\leq 40\%$ )**	N/A	4.7%	6.8%	6.2%	5.96%	Higher is better
3. Antibiotics Utilization ( $\leq 30\%$ )	N/A	21.9%	24.1%	21.8%	20.74%	Higher is better



\*Valid episodes in 2022 performance period across all three MCOs

\*\* This gain-sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.



# Episode gain-sharing Quality Metrics – Wave 9

Wave 9 Episodes*	CY 2019	CY 2020	CY 2021	CY 2022	Target Performance
<b>Cystourethroscopy (1,423 valid episodes)</b>					
1. Difference in Average MED/Day ( $\leq 1.0$ )	0.35	-0.22	0.90	0.82	<i>Lower is better</i>
2. Related ED Visit ( $\leq 10\%$ )	5.4%	5.6%	3.4%	4.64%	<i>Lower is better</i>
3. Repeat cystourethroscopy ( $\leq 5\%$ )	2.8%	2.6%	4.3%	3.58%	<i>Lower is better</i>
<b>Acute Kidney and Ureter Stones (3,171 valid episodes)</b>					
1. Difference in Average MED/Day ( $\leq 3.0$ )	2.49	3.16	1.03	0.89	<i>Lower is better</i>
2. Related ED Visit ( $\leq 15\%$ )	18.9%	16.0%	15.8%	14.08%	<i>Lower is better</i>

\*Valid episodes in 2022 performance period across all three MCOs

